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Abstract
Although the association of common genetic variation in the extended MHC region with
schizophrenia is the most significant yet discovered, the MHC region is one of the more complex
regions of the human genome, with unusually high gene density and long-range linkage
disequilibrium. The statistical test on which the MHC association is based is a relatively simple,
additive model which uses logistic regression of SNP genotypes to predict case-control status.
However, it is plausible that more complex models underlie this association. Using a well-
characterized sample of trios, we evaluated more complex models by looking for evidence for: (a)
non-random mating for HLA alleles, schizophrenia risk profiles, and ancestry; (b) parent-of-origin
effects for HLA alleles; and (c) maternal-fetal genotype incompatibility in the HLA. We found no
evidence for non-random mating in the parents of individuals with schizophrenia in terms of MHC
genotypes or schizophrenia risk profile scores. However, there was evidence of non-random
mating that appeared mostly to be driven by ancestry. We did not detect over-transmission of
HLA alleles to affected offspring via the general TDT test (without regard to parent of origin) or
preferential transmission via paternal or maternal inheritance. We evaluated the hypothesis that
maternal-fetal HLA incompatibility may increase risk for schizophrenia using eight classical HLA
loci. The most significant alleles were in HLA-B, HLA-C, HLA-DQB1, and HLA-DRB1 but none
was significant after accounting for multiple comparisons. We did not find evidence to support
more complex models of gene action, but statistical power may have been limiting.
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Common genetic variation in the major histocompatibility complex (MHC) on 6p22.1 is a
risk factor for many complex human diseases. The association of common genetic variation
in the extended MHC region with schizophrenia is the most significant yet discovered (P
~10−12) (Ripke et al., 2011) and meets community standards in human genetics for
replication (Chanock SJ, 2007). However, the MHC region is one of the more complex
regions of the human genome, with unusually high gene density and long-range linkage
disequilibrium. As a result, the genome-wide significant evidence for association involves
more than 100 SNPs, extends a very large distance (26–33 Mb), and encompasses around
300 genes.
The statistical test on which the MHC association is based is simple, using logistic
regression of SNP genotypes to predict case-control status under an additive model. It is
plausible that more complex models underlie this association. First, non-random mating
(i.e., the tendency for mating partners to have greater phenotypic similarity than expected by
chance) occurs for many physiological traits (Merikangas, 1982) as well as schizophrenia
(Lichtenstein et al., 2006). Non-random mating can lead to complex biases in genomic
studies (Redden and Allison, 2006) and may even be driven by genetic variation in the MHC
region (Havlicek and Roberts, 2009). Second, parent-of-origin effects (variable genetic risk
depending on the parent from which an allele is inherited) can occur in the MHC (Bassett,
2011; Chao et al., 2010). If this mechanism is operative, statistical models explicitly
including such effects could assist in refining the currently broad and ill-defined MHC-
schizophrenia association. Finally, maternal-fetal genotype incompatibility occurs when
specific combinations of maternal and fetal genotypes yield an adverse prenatal environment
(Childs et al., 2011). During pregnancy, maternal antibodies to paternal HLAs can be
detected (Palmer, 2010). Since maternal antibodies to fetal antigens have been observed in a
large proportion of healthy pregnancies, it is possible that maternal recognition or
sensitization of paternally-derived fetal HLAs dissimilar to maternal HLAs may be
beneficial for implantation and maintenance of pregnancy (Palmer et al., 2006). If
paternally-derived fetal HLAs are similar to the maternal HLAs, maternal sensitization can
fail to occur and lead to adverse fetal outcomes. Maternal-fetal genotype incompatibility
may increase the risk of prenatal/obstetric complications (Cowan et al., 1994; Ober et al.,
1998; Schneider et al., 1994; Verp et al., 1993), and there is some evidence that risk of
schizophrenia may also be elevated (Palmer, 2010; Palmer et al., 2006).
Evaluation of these potentially more complex, MHC-themed models is difficult or
impossible to do in case-control studies. Using a well-characterized sample of parent-
affected offspring trios, we evaluated the evidence for: (a) non-random mating for HLA
alleles and MHC SNPs, schizophrenia risk profiles, and ancestry; (b) parent-of-origin effects
for HLA alleles and MHC SNPs; and (c) maternal-fetal genotype incompatibility in the
HLA.
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2. Materials and Methods
2.1. Subjects and genotyping
The study sample comprised 698 parent-offspring trio families from Bulgaria with 727
affected offspring (50.2% male). All subjects were genotyped with Affymetrix 6.0 chips at
the Broad Institute(Ruderfer et al., 2011). We performed quality control (QC) steps in which
we removed subjects with high genotype missing rates (> 2%) or high Mendelian errors per
individual (> 2000 SNPs) along with SNPs with high missing rates (> 2%), strong deviation
from Hardy-Weinberg Equilibrium (p < 1×10−6 in parents although there were none in the
MHC region), frequency difference to HapMap3 CEU (> 0.15)(Altshuler et al., 2010), or
high Mendelian errors per SNP (> 4). After QC, there were 642 probands in 624 complete
trios (607 families with 1 proband, 16 families with 2 probands, and 1 family with 3
probands). Of the 642 probands, 544 (85%) had a diagnosis of schizophrenia and 98 (15%)
schizoaffective disorder (Table S1), and 12 (1.0%) fathers and 36 (2.9%) mothers were
diagnosed with schizophrenia or schizoaffective disorder. We kept 657,466 successfully
genotyped SNPs which contain 1,704 SNPs in the extended MHC region (chr6: 26–33Mb).
In order to impute classical HLA alleles, we used a dataset created by the MHC Working
Group of the Type 1 Diabetes Genetics Consortium (Pereyra et al., 2010). This dataset
contains genotypes (MHC tag SNPs and direct determination of alleles for eight MHC genes
at four digit resolution) for 2,767 unrelated individuals of European ancestry. The eight
MHC genes are HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-
DPA1, and HLA-DPB1 (Brown et al., 2009), and the dataset enables imputation of 377 HLA
alleles, 3,852 SNPs, and 372 amino acid changing polymorphisms. We used Beagle
(Browning and Browning, 2009) to phase and impute classical HLA alleles (Robinson et al.,
2011) for these subjects. We selected 189 HLA alleles imputed with high confidence
(imputation quality > 0.8) and no Mendelian inheritance errors for further analysis.
2.2. Non-Random mating
We evaluated non-random mating in three ways. First, to evaluate non-random mating for
HLA alleles and MHC SNPs, we used methods described in Chaix et al. (Chaix et al., 2008).
The genetic similarity of a mating pair c at a genetic marker in the HLA region was
estimated as R, the ratio of probabilities of identity in state: R=(Qc – Qm) / (1-Qm), where Qc
is the proportion of identical variants in the mating pair (0 if different alleles, 0.5 if one
allele identical, or 1 if both alleles were the same) and Qm is the mean proportion of
identical variants over all possible pairs of individuals in the sample. We summarized R by
computing its mean for mating pairs across the imputed HLA alleles or across SNPs with R
> 0 indicating genetic similarity and R < 0 indicating genetic dissimilarity between mating
pairs relative to random mates in the sample. The significance of R was assessed using
permutation and random shuffling of mating pairs 1,000 times.
Second, we evaluated evidence for non-random mating that might be driven by sub-clinical
phenotypes genetically related to schizophrenia by using risk profile scores (Purcell et al.,
2009) genome-wide, genome-wide excluding MHC, and MHC only. There are robust and
replicable findings that liability to schizophrenia is distributed across the genome and can be
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assessed by a weighted sum of the number of associated risk alleles (Purcell et al., 2009;
Ripke et al., 2011; Ruderfer et al., 2011). We used the PGC schizophrenia sample (Ripke et
al., 2011) as the discovery sample (excluding the subjects from this study) to generate a set
of markers for generating risk profiles in these trios. The risk profile set contained 64,254
SNPs and was a subset of the full GWAS results file after filtering for allele frequency 0.02–
0.98, imputation INFO score > 0.9, approximate linkage equilibrium (r2 ≤ 0.25 within 500kb
windows), and association threshold PT < 0.2 (see Figure S6 in reference (Ripke et al., 2011)
for justification for selection of PT < 0.2). Using this risk profile, we calculated the
schizophrenia risk profile scores for each of the parents in these Bulgarian trios, and
assessed non-random mating via the correlation between mothers and fathers. As a
comparison, we performed the same analysis for the HapMap3 CEU founders. Third, we
evaluated evidence for non-random mating based on ancestry as determined using
multidimensional scaling (MDS) dimensions (Purcell et al., 2007; Sebro et al., 2010) and
again used HapMap3 CEU founders for comparison.
2.3. Parent-of-origin effects
We used the transmission disequilibrium test (Spielman and Ewens, 1993) implemented in
PLINK (Purcell et al., 2007) to determine whether any HLA allele was more frequently
transmitted to the affected offspring than the other allele without regard to the gender of the
transmitting parent. We then refined this general analysis by separately considering
transmissions from heterozygous fathers versus heterozygous mothers to affected offspring
to assess whether the transmission of risk alleles was biased towards one parent.
2.4. Maternal-fetal genotype incompatibility
To evaluate the presence of maternal-fetal genotype incompatibility on risk for
schizophrenia, we used “MFG” option in Mendel (Childs EJ, 2010; Sinsheimer et al., 2003).
The MFG option implements an affected-only likelihood ratio test relying on the joint
estimation of offspring allelic effects, maternal allelic effects, and interactions between
maternal and offspring genotypes. As the Mendel MFG implementation can handle only
biallelic loci, we converted multi-allelic HLA types into binary format and tested for MFG
incompatibility at each biallelic HLA marker. Over all alleles at each HLA locus, we
designated an index allele as “G” (e.g. HLA-A*0101), and “A” for all the other alleles at the
locus. For example, an individual with two HLA-A*0101 alleles would be assigned “G/G” at
marker HLA-A*0101, and an individual with genotype HLA-A*0301/0302 would be
assigned “A/A” at the same marker. With our genotype notation of biallelic HLA marker,
there are 7 possible maternal-child genotype combinations between mother and child (Table
S2). Childs et al. (Childs et al., 2011) and Palmer et al. (Palmer et al., 2006) defined
offspring as being MFG incompatible for a polymorphism if mother and child have identical
genotypes or if the mother is heterozygous and the offspring is homozygous. Following their
definition, we defined the following two combinations as MFG incompatible: (gm= G/G,
gc=G/G), (gm= A/G, gc=G/G) where gm=maternal genotype and gc=child genotype. We did
not consider (gm= A/G, gc=A/A), (gm= A/A, gc=A/A), or (gm= A/G, gc=A/G) as
incompatible since “A” denotes other alleles at the index allele being considered. Mendel
maximizes the log-likelihoods under our MFG incompatibility model and a null model in
which all mother-offspring genotype combinations confer the same risk of disease. For each
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First, we tested for genetic similarity in founders of HapMap2 CEU, HapMap3 CEU, and
our trio sample using imputed HLA alleles (Table S3) and SNPs (Table S4). To calibrate the
method described in (Chaix et al., 2008) and replicate their finding, we repeated the non-
random mating analysis of 5,708 MHC SNPs (chr6: 29.6 −33.3 Mb) with MAF ≥5% in
HapMap2 CEU founders and confirmed the previously reported results (a slight but
statistically significant dissimilarity in the MHC region, R=−0.064, p=0.016). We applied
these procedures to 1,175 MHC SNPs (chr6: 29.6 −33.3 Mb) with MAF ≥1% and to
imputed 4-digit HLA alleles across class I and II genes in 42 mating pairs from HapMap3
CEU. However, unlike the HapMap2 CEU results, there was no evidence for genetic
similarity in HapMap3 CEU based neither on SNPs (R=−0.047, p=0.175) nor on imputed
HLA alleles (six HLA genes, R=0.009, p=0.589; eight HLA genes, R=0.003, p=0.521). Derti
et al. (Derti et al., 2010) suggest that the HapMap2-HapMap3 discrepancy could be due to
influential outliers. Next, we applied similar approaches to 1,082 MHC SNPs (chr6: 29.6
−33.3 Mb) with MAF≥1% and class I and II HLA genes in our sample. Although we
observed marginally significant similarity among parents of schizophrenic offspring using
SNPs (R=0.0082, p=0.052), there was no evidence for similarity using HLA genes (six HLA
genes, R=0.002, p=0.534; eight HLA genes, R=0.004, p=0.804). In summary, we failed to
find evidence to support the hypothesis that parents of schizophrenic offspring are more
likely to be genetically similar in MHC than parents of healthy offspring.
Second, we evaluated non-random mating in regard to risk profile scores derived from PGC
schizophrenia results. As higher risk profile scores have been highly significantly but
weakly correlated with schizophrenia, parents of offspring with schizophrenia are, in
general, likely to have higher risk profile scores than parents of healthy children (Figure S1).
Moreover, if parental mating was influenced by similarity for phenotypic traits related to
risk profile scores, an appreciable positive correlation between parents might be observed.
The genome-wide correlation in risk profile scores between parents was highly significant
(Figure 1, Pearson’s r=0.174, asymptotic p=1.3×10−5, and permutation p < 1×10−4, Figure
S2). However, the paternal-maternal risk profile non-parametric correlation was not
significant (Spearman’s ρ=0.065, p=0.105) (Table 1), suggesting that the Pearson correlation
could be unduly influenced by outliers. After removing 137 ancestral outliers detected by
smartpca in EigenSoft (Price et al., 2006), we found that Pearson’s correlation was no longer
significant (Pearson’s r=−0.07, p=0.11, Figure 1, Table 1). Of the 137 ancestral outliers, 130
individuals were control and 7 were diagnosed with schizophrenia. Correlations excluding
MHC (Pearson’s r=0.16, p=6.1×10−5 ; Spearman’s ρ=0.05, p=0.24) were quite similar to
those including MHC. Correlations in MHC only were null (Pearson’s r=0.01, p=0.76 ;
Spearman’s ρ=−0.03, p=0.52). We applied the same risk score profile to the HapMap3 CEU
founders, and observed non-significant results genome-wide (Pearson’s r=−0.04, p=0.80;
Spearman’s ρ=−0.03, p=0.81; Figure 1, Table 1). Correlations excluding MHC (Pearson’s r=
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−0.02, p=0.90; Spearman’s ρ=0.02, p=0.91) were insignificant, similar to genome-wide
results. Although non-parametric correlations in MHC only were significant (Spearman’s ρ=
−0.32, p=0.01), parametric correlations in MHC were insignificant (Pearson’s r=−0.23,
p=0.08). Taken together, we conclude that there is no strong evidence to support non-
random mating based on schizophrenia risk profile scores calculated across genome-wide or
across MHC in either Bulgarian sample or HapMap3 CEU.
Finally, we assessed non-random mating in regard to genetic ancestry. The first
multidimensional scale score was positively correlated between the parents of probands with
schizophrenia (Pearson’s r=0.92, p<2.2×10−16, and Spearman’s ρ=0.23, p=7.6×10−9),
suggesting ancestry-related non-random mating. After removing 137 ancestry outliers
detected by smartpca, the maternal-paternal correlation was greatly attenuated (r=0.11,
p=0.01, Figure 1, Table 1). There were no significant correlations between intra-parental
scores on the second or third multidimensional scale scores. We also applied the same
procedure to the HapMap3 CEU founders, and observed significant correlations in the first
three MDS values, indicating that there is ancestral non-random mating among the
HapMap3 CEU founders. Even after removing 7 outliers detected by EigenSoft (Price et al.,
2006), correlations in the first three MDS values remained strongly significant. We conclude
that there is supportive evidence for non-random mating with respect to genetic ancestry in
these Bulgarian trios as well as HapMap 3 CEU.
3.2. Association testing
We performed TDT and parent-of-origin analyses on 1704 SNPs in the extended MHC
region (chr6: 26–33Mb) and on 189 HLA alleles with imputation quality > 0.8. TDT
analysis revealed that 4 SNPs (rs2894249, rs2107191, rs3129932, rs3117194), HLA-
DPB1*0201, and HLA-DPB1*1101 were significant (Table 2, Figure S3 for 2-digit HLA
alleles; Figure S4 for 4-digit HLA alleles). However, after multiple testing adjustment using
false discovery rate method (Benjamini, 1995), all the adjusted p-values were greater than
0.6 and hence we concluded that no SNP or HLA allele was significantly over-transmitted to
affected offspring without regard to parents. Parent-of-origin analysis, which separately
considered paternal and maternal over-transmission of risk allele to affected offspring,
suggested that 2 SNPs (rs2107191, rs3117194), HLA-A*0301, HLA-C*1203, and HLA-
DPB1*0201 were over-transmitted paternally whereas 3 SNPs (rs886403, rs1632857,
rs1634717), HLA-A*1101, and HLA-C*0401 were over-transmitted maternally (Table 3,
Figure S3 for 2-digit HLA alleles; Figure S4 for 4-digit HLA alleles). Again, no SNP or
HLA alleles survived after multiple testing adjustments.
3.3. Maternal-fetal genotype incompatibility
We tested the hypothesis of maternal-fetal HLA incompatibility effects on schizophrenia. Of
the 189 HLA alleles tested, 7 alleles in HLA-C, HLA-B, HLA-DRB1, HLA-DQB1 loci
appeared to be associated with schizophrenia (Table 4, Figure S3 for 2-digit HLA alleles;
Figure S4 for 4-digit HLA alleles). Due to previous findings that HLA-B matching effect on
schizophrenia was exclusive to female offspring (Childs et al., 2011; Palmer et al., 2006),
we tested for the MFG incompatibility effects on female probands by performing analyses
on families with female probands. Although we found significant MFG incompatibility
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effects at HLA-B*56 and HLA-B*5601 with all probands, we failed to detect such effects at
HLA-B in female probands (p =0.2 for HLA-B*56 and HLA-B*5601). The MFG
incompatibility effect at HLA-DRB1*01 and HLA-DRB1*0101 remained significant in both
all and female probands. However, after multiple testing correction using false discovery
rate method (Benjamini, 1995), all the adjusted p-values were 1.0.
4. Discussion
Using a relatively large and well-characterized trio sample, our study looked for evidence of
non-random mating, parent-of-origin effects for HLA alleles, and maternal-fetal genotype
incompatibility in the HLA. The results are consistent with three conclusions.
First, there was evidence of non-random mating by ancestry that appeared mostly to be
driven by a subset of subjects who were ancestry outliers. We speculate that this could
reflect within-group mating by minority groups within Bulgaria (e.g., Turks or Roma).
Without data from additional trios sampled without respect to affection status, we cannot
know whether this is a risk factor for schizophrenia or the result of chance, geographic
propinquity, or some other process mechanistically unrelated to schizophrenia. However, we
found no compelling evidence for non-random mating in the parents of individuals with
schizophrenia in terms of MHC genotypes or schizophrenia risk profile scores.
Second, after correcting for multiple testing, we did not detect over-transmission of HLA
alleles to affected offspring via the general TDT test (without regard to parent of origin) or
preferential transmission via paternal or maternal inheritance.
Third, we evaluated the hypothesis that maternal-fetal HLA incompatibility may increase
risk for schizophrenia by examining the effect of maternal-fetal HLA matching in all
probands, female probands using imputed alleles of eight classical HLA loci. The most
significant alleles were in HLA-B, HLA-C, HLA-DQB1, HLA-DRB1 but none was significant
after accounting for multiple comparisons. In contrast to the more general and less
assumption-laden approach we chose, Palmer et al. (Palmer, 2010; Palmer et al., 2006) and
Childs et al. (Childs et al., 2011) applied a modified MFG test to three multi-allelic loci of
HLA-A, HLA-B, and HLA-DRB1. They observed an association between HLA-B matching
and schizophrenia in female offspring. Although we found significant HLA-B matching
effect using families with all probands, we failed to replicate HLA-B matching effect using
families with female probands only. Failure of replication could be due to methodological
differences or different population (Finland versus Bulgaria) or HLA typing (imputed versus
genotyped) or different sample sizes (274 families versus 624 families). Regarding
methodological differences, they combined alleles to reduce the number of allele
frequencies estimated at each locus and tested for HLA matching effect on schizophrenia at
each HLA locus as a whole whereas we tested for HLA matching effect at each allele of
each HLA locus. As discussed in their paper, however, combining alleles may result in
binning low-risk mother-offspring combinations with high-risk ones. Different results may
be obtained depending on how to combine the alleles.
These analyses must be viewed in context of several limitations. First, although the present
sample is, to our knowledge, the largest trio sample with GWAS data available for
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schizophrenia, it is possible that true effects could have gone undetected due to limited
power. As an illustration, for one of our hypotheses involving the general TDT, we had 80%
power to detect genotypic relative risks of 1.37 and 1.79 for minor allele frequencies of 0.30
and 0.05 (624 case-parent trios, α=0.00625 (8 tests), log-additive model, and 0.4% disease
risk in the general population) (Gauderman, 2006). These effect sizes are quite large (Ripke
et al., 2011) and thus power was probably insufficient, although we have no strong
precedents with which to derive effect size expectations under the more complex models.
Second, other models such as a model including gene by environment interaction are
possible. Third, this Bulgarian sample is atypical in terms of frequency and effect size of the
ancestral haplotype across European samples as the ISC study (Purcell et al., 2009)
originally documented.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Spousal correlation in Bulgarian sample and HapMap3 CEU using polygene scores
Upper panels depict polygene risk scores and MDS1 of Bulgarian founders. Black dots
indicate genetic outliers detected by Eigenstrat. Solid red line represents a regression line
when including all pairs. Dotted line represents a regression line after removing the genetic
outliers. Lower panels show polygene risk scores and MDS1 of HapMap 3 CEU founders.
Kim et al. Page 12











































Kim et al. Page 13
Table 1
Summary of non-random mating using risk profile scores and multidimensional scaling (MDS).
Bulgarian Families HapMap3 CEU
Pearson correlation (p-value) Spearman correlation (p-value) Pearson correlation (p-value) Spearman correlation (p-value)
 (a) Risk score profile




−0.07 (0.11) −0.05 (0.28) NA NA
Excluding MHC 0.16 (6.1E-5) 0.05 (0.24) −0.02 (0.90) 0.02 (0.91)
MHC only 0.01 (0.76) −0.03 (0.52) −0.23 (0.08) −0.32 (0.01)
 (b) MDS




0.11 (0.01) 0.12 (0.006) 0.54 (0.001) 0.52 (0.002)
MDS2 −0.02 (0.69) 0.08 (0.05) 0.90 (8.9E-16) 0.86 (< 2.2E-16)
MDS3 0.01 (0.73) −0.004 (0.92) 0.98 (< 2.2E-16) 0.95 (< 2.2E-16)
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Table 4
Summary of MFG incompatibility test.









: Families with all probands were included in analysis.
2
: Families with female probands were included in analysis.
Schizophr Res. Author manuscript; available in PMC 2014 October 15.
